Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
H
|
Honeywell International Inc
XMUN:ALD
|
US |
|
APi Group Corp
F:4XY
|
US |
|
B
|
Boston Scientific Corp
F:BSX
|
US |
|
R
|
Ramada Investimentos e Industria SA
F:Y4E
|
PT |
|
K
|
Kering SA
XMUN:PPX
|
FR |
|
F
|
First Advantage Corp
NASDAQ:FA
|
US |
|
C
|
Corcept Therapeutics Inc
SWB:HTD
|
US |
|
O
|
Orlen SA
PSE:PKN
|
PL |
|
R
|
RWE AG
DUS:RWE
|
DE |
|
Sands China Ltd
F:599
|
MO |
|
C
|
China Pacific Insurance Group Co Ltd
F:75CB
|
CN |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 386.4 EUR with a low forecast of 202.53 EUR and a high forecast of 504.98 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
386.4
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 386.4 EUR with a low forecast of 202.53 EUR and a high forecast of 504.98 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 8 years is 36%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Net Income over the next 8 years is 41%.
